M1401 HCPCS code: Stages i-iii breast cancer
M1401 is the HCPCS Level II code for stages i-iii breast cancer. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | M codes — Medical services and quality measures |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 00 — Not separately priced by Medicare |
| BETOS category | Z2 |
| Added | 2025-01-01 |
| Last action effective | 2025-01-01 |
What changed for M1401
- 2025-01-01: M1401 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code M1401?
M1401 is the HCPCS Level II code for stages i-iii breast cancer. Short descriptor: "Stg i-iii br ca".
Does Medicare cover M1401?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Related M14 codes
- M1400 — Patients who died during the follow-up period
- M1402 — Patients receiving an initial chemotherapy regimen with a defined duration with the eligible clinician or group
- M1403 — Patients with baseline and follow-up promis surveys documented in the medical record
- M1404 — Patients on a therapeutic clinical trial
- M1405 — Patients with recurrence/disease progression
- M1406 — Patients who leave the practice during the follow-up period
- M1407 — Patients who died during the follow-up period
- M1408 — Patients who have germline brca testing completed before diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer
- M1409 — Patients who received germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1410 — Patients who did not have germline testing for brca1 and brca2 or genetic counseling completed within 6 months of diagnosis
- M1411 — Currently on first-line immune checkpoint inhibitors without chemotherapy
- M1412 — Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under M1401
- Watch M1401 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for M1401
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.